Skip to main content
Erschienen in: Wiener klinisches Magazin 6/2019

18.11.2019 | Myeloproliferative Syndrome | Onkologie

Zweitlinientherapie bei BCR-ABL-negativen myeloproliferativen Neoplasien

Therapieentscheidungen außerhalb von klinischen Studien

verfasst von: OA Dr. Sonja Heibl

Erschienen in: Wiener klinisches Magazin | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Ziel der Therapie BCR-ABL-negativer myeloproliferativer Neoplasien (MPN) ist einerseits die Verhinderung des Auftretens thromboembolischer Komplikationen und andererseits die Transformation in eine Myelofibrose oder akute Leukämie. Nach Versagen der Erstlinientherapie ist die vorhandene Datenlage über den Einsatz medikamentöser Therapiestrategien sehr spärlich, sodass in diesem Artikel versucht wird, die Möglichkeiten der Zweitlinientherapie basierend auf vorhanden Daten und Erfahrung herauszuarbeiten.
Literatur
1.
Zurück zum Zitat Arber DA et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405CrossRef Arber DA et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405CrossRef
2.
Zurück zum Zitat Tefferi A et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27:1874–1881CrossRef Tefferi A et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27:1874–1881CrossRef
3.
Zurück zum Zitat Barbui T et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761–770CrossRef Barbui T et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761–770CrossRef
4.
Zurück zum Zitat Landolfi R et al (2004) Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera. N Engl J Med 350:114–124CrossRef Landolfi R et al (2004) Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera. N Engl J Med 350:114–124CrossRef
5.
Zurück zum Zitat Marchioli R et al (2013) Cardiovascular events and intensity of treatment of polycythemia vera. N Engl J Med 368:22–33CrossRef Marchioli R et al (2013) Cardiovascular events and intensity of treatment of polycythemia vera. N Engl J Med 368:22–33CrossRef
6.
Zurück zum Zitat Barbui T et al (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32:1057–1069CrossRef Barbui T et al (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32:1057–1069CrossRef
7.
Zurück zum Zitat Burgstaller S et al (2018) Austrian recommendations for the management of polycythemia vera. Wien Klin Wochenschr 130:535–542CrossRef Burgstaller S et al (2018) Austrian recommendations for the management of polycythemia vera. Wien Klin Wochenschr 130:535–542CrossRef
8.
Zurück zum Zitat Kiladjian JJ et al (2008) Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112:3065–3072CrossRef Kiladjian JJ et al (2008) Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112:3065–3072CrossRef
9.
Zurück zum Zitat Quintas-Cardama A et al (2009) Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27:5418–5424CrossRef Quintas-Cardama A et al (2009) Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27:5418–5424CrossRef
10.
Zurück zum Zitat Mascarenhas J et al (2018) Results of the Myeloproliferative Neoplasms—Research Consortium (MPN-RC) 112 randomized trial of pegylated interferon alfa-2a (PEG) versus Hydroxyurea (HU) therapy for the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET). Blood 132(Suppl 1):577CrossRef Mascarenhas J et al (2018) Results of the Myeloproliferative Neoplasms—Research Consortium (MPN-RC) 112 randomized trial of pegylated interferon alfa-2a (PEG) versus Hydroxyurea (HU) therapy for the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET). Blood 132(Suppl 1):577CrossRef
11.
Zurück zum Zitat Gisslinger H et al (2018) Evidence of superior efficacy and disease modification after three years of prospective randomized controlled treatment of polycythemia vera patients with ropeginterferon alfa-2b vs. HU/BAT. Blood 132(Suppl 1):579CrossRef Gisslinger H et al (2018) Evidence of superior efficacy and disease modification after three years of prospective randomized controlled treatment of polycythemia vera patients with ropeginterferon alfa-2b vs. HU/BAT. Blood 132(Suppl 1):579CrossRef
13.
Zurück zum Zitat Vanucchi AM et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372:426–435CrossRef Vanucchi AM et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372:426–435CrossRef
14.
Zurück zum Zitat Passamonti F et al (2017) Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly (RESPONSE-2): a randomized, open-label, phase 3b study. Lancet Oncol 18:88–99CrossRef Passamonti F et al (2017) Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly (RESPONSE-2): a randomized, open-label, phase 3b study. Lancet Oncol 18:88–99CrossRef
15.
Zurück zum Zitat Mesa R et al (2017) The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythemia vera: a randomized, double-blind, double-dummy, symptom study. Br J Haematol 176:76–85CrossRef Mesa R et al (2017) The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythemia vera: a randomized, double-blind, double-dummy, symptom study. Br J Haematol 176:76–85CrossRef
16.
Zurück zum Zitat Alvarez-Larrán A et al (2007) Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia 21:1218–1223CrossRef Alvarez-Larrán A et al (2007) Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia 21:1218–1223CrossRef
17.
Zurück zum Zitat Cortelazzo S et al (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New Engl J Med 332:1132–1136CrossRef Cortelazzo S et al (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New Engl J Med 332:1132–1136CrossRef
18.
Zurück zum Zitat Harrison C et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33–45CrossRef Harrison C et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33–45CrossRef
19.
Zurück zum Zitat Gisslinger H et al (2013) Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood 121:1720–1728CrossRef Gisslinger H et al (2013) Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood 121:1720–1728CrossRef
20.
Zurück zum Zitat Sliwa T et al (2017) Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement. Wien Klin Wochenschr 129:293–302CrossRef Sliwa T et al (2017) Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement. Wien Klin Wochenschr 129:293–302CrossRef
21.
Zurück zum Zitat Harrsion C et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787–798CrossRef Harrsion C et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787–798CrossRef
22.
Zurück zum Zitat Verstovsek S et al (2012) Double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799–807CrossRef Verstovsek S et al (2012) Double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799–807CrossRef
23.
Zurück zum Zitat Mesa RA et al (2006) Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 107:361–370CrossRef Mesa RA et al (2006) Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 107:361–370CrossRef
Metadaten
Titel
Zweitlinientherapie bei BCR-ABL-negativen myeloproliferativen Neoplasien
Therapieentscheidungen außerhalb von klinischen Studien
verfasst von
OA Dr. Sonja Heibl
Publikationsdatum
18.11.2019
Verlag
Springer Vienna
Erschienen in
Wiener klinisches Magazin / Ausgabe 6/2019
Print ISSN: 1869-1757
Elektronische ISSN: 1613-7817
DOI
https://doi.org/10.1007/s00740-019-00318-z

Weitere Artikel der Ausgabe 6/2019

Wiener klinisches Magazin 6/2019 Zur Ausgabe

Panorama

Panorama